Aug 27, 2024 8:00am EDT SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
Aug 08, 2024 4:30pm EDT SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 23, 2024 7:00am EDT SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
May 08, 2024 4:30pm EDT SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 30, 2024 4:05pm EDT SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
Apr 09, 2024 4:05pm EDT SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Mar 28, 2024 4:01pm EDT SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
Jan 29, 2024 5:15pm EST SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
Jan 05, 2024 8:30am EST SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
